Collins Richard Alexander, an insider at Dexcom Inc (DXCM), sold 37,994 shares of the company on November 9, 2025, at a price of $55.17 per share, resulting in a total transaction value of $2.10 million. Following this sale, Alexander retains 37,994 shares in the company.
Dexcom, headquartered in San Diego, California, is a prominent player in the health care sector, specialising in the design and development of continuous glucose monitoring systems for diabetes management. The firm has a market capitalisation of $22.6 billion and a price-to-earnings ratio of 31.40, with earnings per share reported at 1.77.
Insider transactions, such as this sale, are reported to the SEC and provide insight into how company executives perceive their stock. However, such activities should not be the sole basis for investment decisions, as they can stem from various personal or regulatory motivations. Investors are encouraged to consider broader patterns of insider activity across multiple individuals and time periods.
Looking ahead, Dexcom is expected to report its earnings on July 27, 2026, with an estimated EPS of $0.63 and revenue of $1.4 billion, following an earlier report on April 28, 2026, with an estimated EPS of $0.48 and revenue of $1.2 billion.